Clinical effects of miR-101 on prognosis of hepatocellular carcinoma and carcinogenic mechanism of anti-miR-101

Lv,Xuecheng; Li,Jinghua; Yang,Bingnan

doi:10.3892/or.2016.4980

Clinical effects of miR-101 on prognosis of hepatocellular carcinoma and carcinogenic mechanism of anti-miR-101

Authors:
- Xuecheng Lv
- Jinghua Li
- Bingnan Yang
View Affiliations

Affiliations: Department of Pharmacy, The First People's Hospital of Shangqiu, Shangqiu, Henan 476100, P.R. China, Department of Cardiovascular Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan 450000, P.R. China, Department of Neurosurgery, Henan Provincial People's Hospital, Zhengzhou, Henan 450000, P.R. China
Published online on: July 28, 2016 https://doi.org/10.3892/or.2016.4980
Pages: 2184-2192

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to verify whether anti-miR-101 participates in the treatment of hepatocellular carcinoma (HCC) as a small-molecule antitumor agent, and to explore the effect on phosphatase and tensin homolog deleted on chromosome 10 (PTEN). Patients who received consecutive hepatectomies were followed-up, and miR-101 expressions in their tumor and paracancerous tissues were detected. Correlation between miR-101 expression and clinical pathological factors and prognosis was studied. High‑throughput sequencing was used to detect the genetic and microRNA (miRNA) levels of tumor tissues. Expression of anti-miR-101 in different HCC cell lines was determined, and those of desired genes and proteins were detected by qRT-PCR and western blotting to obtain the target gene. miR-101 was significantly upregulated in HCC patients compared with that in paracancerous tissues. High miR-101 expression, vascular invasion, tumor size ≥7 cm and late pathological stage were the risk factors of recurrence-free survival rate. High miR-101 expression was the independent prognostic factor of total and recurrence-free survival rates. CXCL12, IL6R, FOXO3 and PTEN were screened as desired genes, and only PTEN was expressed significantly differently in three cell lines. miR-101 could bind 3'-UTR of WT-PTEN with reduced fluorescent intensity, suggesting that PTEN was the target gene. SMMC-7721, HepG2 and Huh7 were eligible cell lines for miR-101 studies. miR-101 was an applicable molecular marker of HCC. Anti-miR-101 regulated the transcription of PTEN and may promote cell proliferation, differentiation and apoptosis by regulating downstream genes with PTEN. The regulatory effects of anti-miR-101 on PTEN provide valuable evidence for finding novel miRNA drugs.

View Figures

View References

1	Fang M, Zhao YP, Zhou FG, Lu LG, Qi P, Wang H, Zhou K, Sun SH, Chen CY and Gao CF: N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma. Int J Cancer. 127:148–159. 2010. View Article : Google Scholar
2	Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM and Poon RT: Biology of hepatocellular carcinoma. Ann Surg Oncol. 15:962–971. 2008. View Article : Google Scholar : PubMed/NCBI
3	Shao Q, Ren P, Li Y, Peng B, Dai L, Lei N, Yao W, Zhao G, Li L and Zhang J: Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma. Int J Oncol. 41:1061–1067. 2012.PubMed/NCBI
4	Wang L, Li B, Li L and Wang T: MicroRNA-497 suppresses proliferation and induces apoptosis in prostate cancer cells. Asian Pac J Cancer Prev. 14:3499–3502. 2013. View Article : Google Scholar : PubMed/NCBI
5	Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y and Zhuang SM: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 69:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI
6	Saumet A, Vetter G, Bouttier M, Antoine E, Roubert C, Orsetti B, Theillet C and Lecellier CH: Estrogen and retinoic acid antagonistically regulate several microRNA genes to control aerobic glycolysis in breast cancer cells. Mol Biosyst. 8:3242–3253. 2012. View Article : Google Scholar : PubMed/NCBI
7	Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, et al: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008. View Article : Google Scholar : PubMed/NCBI
8	Saito A, Suzuki HI, Horie M, Ohshima M, Morishita Y, Abiko Y and Nagase T: An integrated expression profiling reveals target genes of TGF-β and TNF-α possibly mediated by microRNAs in lung cancer cells. PLoS One. 8:e565872013. View Article : Google Scholar
9	Piepoli A, Tavano F, Copetti M, Mazza T, Palumbo O, Panza A, di Mola FF, Pazienza V, Mazzoccoli G, Biscaglia G, et al: Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One. 7:e336632012. View Article : Google Scholar : PubMed/NCBI
10	Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, Castellano L, Magrelli A, Citarella F, Messina M, et al: Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 109:4944–4951. 2007. View Article : Google Scholar : PubMed/NCBI
11	Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, et al: In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 147:382–395. 2011. View Article : Google Scholar : PubMed/NCBI
12	Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, et al: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 147:344–357. 2011. View Article : Google Scholar : PubMed/NCBI
13	Lee SS, Shin HS, Kim HJ, Lee SJ, Lee HS, Hyun KH, Kim YH, Kwon BW, Han JH, Choi H, et al: Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: A single-center experience. Korean J Hepatol. 18:48–55. 2012. View Article : Google Scholar : PubMed/NCBI
14	Ang SF, Tan SH, Toh HC, Poon DY, Ong SY, Foo KF and Choo SP: Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. Am J Clin Oncol. 35:222–227. 2012. View Article : Google Scholar
15	Zhou L, Rui JA, Wang SB, Chen SG and Qu Q: Risk factors of poor prognosis and portal vein tumor thrombosis after curative resection of solitary hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 12:68–73. 2013. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Deng ZS, Liao MM, Wang N, Zhang XQ, Yu HY and Zhang YD: Tumor associated glycoprotein-72 is a novel marker for poor survival in hepatocellular carcinoma. Pathol Oncol Res. 18:911–916. 2012. View Article : Google Scholar : PubMed/NCBI
17	Yang W, Sun T, Cao J, Liu F, Tian Y and Zhu W: Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp Cell Res. 318:944–954. 2012. View Article : Google Scholar : PubMed/NCBI
18	Guo J, Yao F, Lou Y, Xu C, Xiao B, Zhou W, Chen J, Hu Y and Liu Z: Detecting carcinoma cells in peripheral blood of patients with hepatocellular carcinoma by immunomagnetic beads and rt-PCR. J Clin Gastroenterol. 41:783–788. 2007. View Article : Google Scholar : PubMed/NCBI
19	Zheng X, Pan C, Diao Y, You Y, Yang C and Hu Z: Development of microsatellite markers by transcriptome sequencing in two species of Amorphophallus (Araceae). BMC Genomics. 14:4902013. View Article : Google Scholar : PubMed/NCBI
20	Xia H, Zhao C, Hou L, Li A, Zhao S, Bi Y, An J, Zhao Y, Wan S and Wang X: Transcriptome profiling of peanut gynophores revealed global reprogramming of gene expression during early pod development in darkness. BMC Genomics. 14:5172013. View Article : Google Scholar : PubMed/NCBI
21	Gorur A, Balci Fidanci S, Dogruer Unal N, Ayaz L, Akbayir S, Yildirim Yaroglu H, Dirlik M, Serin MS and Tamer L: Determination of plasma microRNA for early detection of gastric cancer. Mol Biol Rep. 40:2091–2096. 2013. View Article : Google Scholar
22	Burgucu D, Guney K, Sahinturk D, Ozbudak IH, Ozel D, Ozbilim G and Yavuzer U: Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma. BMC Cancer. 12:4812012. View Article : Google Scholar : PubMed/NCBI
23	Ekizoglu S, Dalay N, Karaman E, Akdeniz D, Ozaydin A and Buyru N: LKB1 downregulation may be independent of promoter methylation or FOXO3 expression in head and neck cancer. Transl Res. 162:122–129. 2013. View Article : Google Scholar : PubMed/NCBI
24	de Oliveira KB, Guembarovski RL, Guembarovski AM, da Silva do Amaral Herrera AC, Sobrinho WJ, Ariza CB and Watanabe MA: CXCL12, CXCR4 and IFNγ genes expression: Implications for proinflammatory microenvironment of breast cancer. Clin Exp Med. 13:211–219. 2013. View Article : Google Scholar
25	Tsukamoto K, Ohta N, Shirai Y and Emi M: A highly polymorphic CA repeat marker at the human interleukin 6 receptor (IL6R) locus. J Hum Genet. 43:289–290. 1998. View Article : Google Scholar : PubMed/NCBI
26	Fulzele A, Malgundkar SA, Govekar RB, Patil A, Kane SV, Chaturvedi P, D'Cruz AK and Zingde SM: Proteomic profile of keratins in cancer of the gingivo buccal complex: Consolidating insights for clinical applications. J Proteomics. 91:242–258. 2013. View Article : Google Scholar : PubMed/NCBI
27	Dou LP, Li YH, Wang LL and Yu L: HOXA9 is direct target of miR-196a. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 27:166–169. 2011.In Chinese. PubMed/NCBI
28	Wang YP, Tang XJ, Chen XH, Che GW, Zhu DX, Sun ZL and Zhou QH: Study on cloning of hTERT promoter and its targeting transcriptional activities in telomerase-positive lung cancer cells. Sichuan Da Xue Xue Bao Yi Xue Ban. 37:497–501. 2006.In Chinese. PubMed/NCBI
29	Zhi Q, Zhu J, Guo X, He S, Xue X, Zhou J, Hu B, Li H, Chen S, Zhao H, et al: Metastasis-related miR-185 is a potential prognostic biomarker for hepatocellular carcinoma in early stage. Biomed Pharmacother. 67:393–398. 2013. View Article : Google Scholar : PubMed/NCBI
30	Katayama Y, Maeda M, Miyaguchi K, Nemoto S, Yasen M, Tanaka S, Mizushima H, Fukuoka Y, Arii S and Tanaka H: Identification of pathogenesis-related microRNAs in hepatocellular carcinoma by expression profiling. Oncol Lett. 4:817–823. 2012.PubMed/NCBI
31	Kim WH, Min KT, Jeon YJ, Kwon CI, Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, Hwang SG, et al: Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. Gene. 504:92–97. 2012. View Article : Google Scholar : PubMed/NCBI
32	Furnari FB, Lin H, Huang HS and Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA. 94:12479–12484. 1997. View Article : Google Scholar : PubMed/NCBI
33	Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, et al: Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 57:4710–4713. 1997.PubMed/NCBI
34	Inaba N, Kimura M, Fujioka K, Ikeda K, Somura H, Akiyoshi K, Inoue Y, Nomura M, Saito Y, Saito H, et al: The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells. Anticancer Res. 31:1653–1658. 2011.PubMed/NCBI
35	Barbosa M, Henrique M, Pinto-Basto J, Claes K and Soares G: Prostate cancer in Cowden syndrome: Somatic loss and germline mutation of the PTEN gene. Cancer Genet. 204:224–225. 2011. View Article : Google Scholar : PubMed/NCBI
36	Ogita S and Lorusso P: Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Target Oncol. 6:103–117. 2011. View Article : Google Scholar : PubMed/NCBI
37	Karra L, Shushan A, Ben-Meir A, Rojansky N, Klein BY, Shveiky D, Levitzki R and Ben-Bassat H: Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: Possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology. Fertil Steril. 93:2646–2651. 2010. View Article : Google Scholar
38	Kim HA, Kim KJ, Seo KH, Lee HK and Im SY: PTEN/MAPK pathways play a key role in platelet-activating factor-induced experimental pulmonary tumor metastasis. FEBS Lett. 586:4296–4302. 2012. View Article : Google Scholar : PubMed/NCBI
39	Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP and Eng C: Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 92:924–930. 2000. View Article : Google Scholar : PubMed/NCBI
40	Chen Y, Sun Y, Chen L, Xu X, Zhang X, Wang B, Min L and Liu W: miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep. 7:1579–1584. 2013.PubMed/NCBI
41	Xiong X, Ren HZ, Li MH, Mei JH, Wen JF and Zheng CL: Down-regulated miRNA-214 induces a cell cycle G1 arrest in gastric cancer cells by up-regulating the PTEN protein. Pathol Oncol Res. 17:931–937. 2011. View Article : Google Scholar : PubMed/NCBI